-

09:56:15 PM

TARS Stock News

TARS - Tarsus Pharmaceuticals Inc

09/06/23 8:00 AM

Nasdaq : TARS

fda approval

Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, MD, PhD, Chief

RHEA-AI

negative

08/30/23 4:30 PM

Nasdaq : TARS

conferences

Tarsus to Present at Upcoming Investor Conferences

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D.,

RHEA-AI

neutral

08/24/23 9:00 AM

Nasdaq : TARS

fda approval

Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis

Demodex blepharitis impacts approximately 25 million eye care patients in the U.S. – or 1 out of every 12 adults. XDEMVY is indicated for all adult patients with Demodex blepharitis and is available via prescription from an eye care provider Sales force deployed, calling on ophthalmologists and

RHEA-AI

neutral

08/10/23 4:05 PM

Nasdaq : TARS

earnings

Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements

XDEMVY™ (lotilaner ophthalmic solution) 0.25% received FDA approval for the treatment for Demodex blepharitis On track to have XDEMVY and sales force in market by the end of August 2023 Completed enrollment of Galatea, a Phase 2a trial evaluating TP-04 for Rosacea, with topline data expected in 1H

RHEA-AI

neutral

08/01/23 10:30 PM

Nasdaq : TARS

offering

Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock

Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the

RHEA-AI

neutral

07/31/23 4:29 PM

Nasdaq : TARS

offering

Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock

Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the

RHEA-AI

neutral

07/25/23 7:00 AM

Nasdaq : TARS

fda approval

FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis

XDEMVY is the first and only approved therapeutic for Demodex blepharitis, a highly prevalent eyelid disease that impacts approximately 25 million eye care patients in the U.S. XDEMVY targets the root cause of Demodex blepharitis and has demonstrated efficacy across multiple clinical measures of

RHEA-AI

neutral

06/05/23 8:30 AM

Nasdaq : TARS

conferences

Tarsus to Present at the Jefferies Global Healthcare Conference

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D.,

RHEA-AI

neutral

05/09/23 4:05 PM

Nasdaq : TARS

earnings

Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements

Continuing to build market awareness through disease education and deploying commercial leadership in anticipation of TP-03 August 25, 2023 PDUFA Presented health economics data suggesting a costly and substantial burden of illness in patients with Demodex blepharitis Tarsus to host investor

RHEA-AI

neutral

05/08/23 8:30 AM

Nasdaq : TARS

Tarsus Launches “Don’t Freak Out. Get Checked Out.” Campaign During Healthy Vision Month to Encourage Patients with Demodex Blepharitis to Visit Eye Care Providers

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

TARS Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitetarsusrx.com
Security nameTarsus Pharmaceuticals Inc
SectorManufacturing
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Medicinal and Botanical Manufacturing

About Tarsus Pharmaceuticals Inc

tarsus pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. its lead product candidate is tp-03, a novel therapeutic that is in phase iib/iii for the treatment of blepharitis caused by the infestation of demodex mites, as well as to treat meibomian gland disease. the company is also developing tp-04 for the treatment of rosacea; and tp-05 for lyme prophylaxis and community malaria reduction. tarsus pharmaceuticals, inc. was founded in 2016 and is headquartered in irvine, california.